NCT01822080View on ClinicalTrials.gov

Phase 3 Study of Dienogest for the Treatment of Endometriosis in Chinese Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

November 30, 2015

Conditions
Endometriosis
Interventions
DRUG

Dienogest (Visanne, BAY86-5258)

2 mg dienogest (DNG) once daily by mouth

DRUG

Placebo

Matching placebo once daily by mouth

Trial Locations (26)

100020

Beijing

100026

Beijing

100029

Beijing

100032

Beijing

100034

Beijing

100038

Beijing

100044

Beijing

100083

Beijing

110004

Shenyang

116011

Dalian

200011

Shanghai

200030

Shanghai

200127

Shanghai

400010

Chongqing

400016

Chongqing

400042

Chongqing

421001

Hengyang

430030

Wuhan

510120

Guangzhou

610041

Chengdu

610072

Chengdu

710061

Xi'an

050000

Shijiazhuang

Unknown

Changchun

Hangzhou

Kunming

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY